Register entry
AMYLYX PHARMACEUTICALS INC
- Registered sites
- 0
- Active NDC listings
- 0
- Live patents
- 5
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
5| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 10251896 | RELYVRIOsodium phenylbutyrate; taurursodiol | use | Dec 2033 |
| 10857162 | RELYVRIOsodium phenylbutyrate; taurursodiol | use | Dec 2033 |
| 11071742 | RELYVRIOsodium phenylbutyrate; taurursodiol | product | Dec 2033 |
| 9872865 | RELYVRIOsodium phenylbutyrate; taurursodiol | use | Dec 2033 |
| 11583542 | RELYVRIOsodium phenylbutyrate; taurursodiol | product | Jul 2040 |
| Product | Exclusivity | Until |
|---|---|---|
| RELYVRIOSODIUM PHENYLBUTYRATE; TAURURSODIOL | ODE-411 Orphan drug | Sept 2029 |
Enquiry
Common questions
- Is AMYLYX PHARMACEUTICALS INC FDA approved?
- AMYLYX PHARMACEUTICALS INC holds no registered establishment of its own; it appears here on its Orange Book patents.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.